Merck & Company Inc
MRK#60 of 134 by buybacksNYSE · Healthcare · Drug Manufacturers - General · USA
merck.comBuybacks · TTM to Jun 2026$4.21Blatest four quarters
Buyback yield1.2%repurchases ÷ market cap
Dividends · TTM to Jun 2026$8.30Bdividend yield 2.3%
Shareholder yield3.5%buybacks + dividends ÷ market cap
Shares outstanding · 5 yr−2.5%2.47B shares (2026)
Buybacks ÷ free cash flow26%payout incl. dividends 78%
Fiscal-year detail
From the cash-flow statement as reported, in USD. Negative repurchases mean net share issuance.
| Fiscal year | Repurchases | Dividends | Free cash flow |
|---|---|---|---|
| FY2025Dec 2025 | $5.08B | $8.18B | $12.4B |
| FY2024Dec 2024 | $1.31B | $7.84B | $18.1B |
| FY2023Dec 2023 | $1.35B | $7.45B | $9.14B |
| FY2022Dec 2022 | −$384M | $7.01B | $14.7B |
| FY2021Dec 2021 | $840M | $6.61B | $9.66B |
| FY2020Dec 2020 | $1.28B | $6.21B | $5.57B |
| FY2019Dec 2019 | $4.78B | $5.70B | $9.97B |
Repurchases in FY2025 were +289.3% versus the prior year.
About Merck & Company Inc
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and ser…
- Market cap
- $359B
- P/E (trailing)
- 115.6×
- Fiscal year end
- December
- ISIN
- US58933Y1055
- Reporting currency
- USD
- Data updated
- Oct 10, 2026